CheckMate 901: Characterizing Complete Responders, Patients With Lymph Node-Only mUC

Matthew Galsky, MD, of Icahn School of Medicine at Mount Sinai, and Amanda Nizam, MD, of Cleveland Clinic, break down the latest data subanalysis from the CheckMate 901 trial.

Together, they characterize complete responders to nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma.

View their continued conversation on Disitamab Vedotin With Pembrolizumab Versus Chemotherapy for la/mUC Expressing HER2.